12.88p+0.00 (+0.00%)05 Jul 2022, 13:58
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Scancell Holdings PLC Fundamentals

Company NameScancell Holdings PLCLast Updated2022-07-05
Shares in Issue815.219 mMarket Cap£104.96 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.02EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.1782Debt Equity Ratio0.3312
Asset Equity Ratio1.9699Cash Equity Ratio1.5675
Quick Ratio22.7929Current Ratio24.05
Price To Book Value4.6253ROCE0

Scancell Holdings PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Scancell Holdings PLC Company Financials

Tangible Assets£975,000.00£195,000.00£58,000.00
Intangible Assets£3.42 m£3.42 m£3.42 m
Total Fixed Assets£4.39 m£3.61 m£3.47 m
Cash & Equivalents£41.11 m£3.58 m£4.56 m
Other Assets000
Total Assets£49.06 m£8.82 m£10.54 m
Creditors within 1 year£2.29 m£1.09 m£1.21 m
Creditors after 1 year£27.28 m£79,000.000
Other Liabilities000
Total Liabilities£29.57 m£1.17 m£1.21 m
Net assets£19.48 m£7.65 m£9.34 m
Called up share capital£815,000.00£465,000.00£388,000.00
Share Premium£65.02 m£38.39 m£34.64 m
Profit / Loss-£16.80 m-£6.77 m-£6.71 m
Other Equity£19.48 m£7.65 m£9.34 m
Preference & Minorities000
Total Capital Employed£19.48 m£7.65 m£9.34 m
Debt Ratio£0.44£0.010
Assets / Equity1.96991.96991.9699
Cash / Equity1.56751.56751.5675
Cash Flow202120202019
Cash from operating activities-£7.80 m-£4.77 m-£7.03 m
Cashflow before financing£38.28 m-£972,000.00-£5.76 m
Increase in Cash£37.53 m-£985,000.00-£5.74 m
Cost of sales000
Gross Profit000
Operating Profit-£8.83 m-£6.78 m-£6.73 m
Pre-Tax profit-£16.80 m-£6.77 m-£6.71 m

Scancell Holdings PLC Company Background

ActivitiesScancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.
Latest Interim Date26 Jan 2022
Latest Fiscal Year End Date29 Oct 2021

Scancell Holdings PLC Directors

2018-08-31Ms. Kate Cornish-Bowden Non-Executive Director
2016-09-16Mr. David Eric EvansNon-Executive Director,Chairman
2014-05-09Mr. Peter Vance AllenNon-Executive Director
2021-10-29Dr. John ChiplinExecutive Director,Chairman
2021-09-09Professor Linda Gillian DurrantExecutive Director,Chief Executive Officer and Chief Scientific Officer
2021-10-29Dr. Richard Morley GoodfellowNon-Executive Director
2012-12-12Mr. Nigel James Forrester EvansNon-Executive Director,Company Secretary
2013-02-27Mr. Thomas Michael RipponNon-Executive Director
2019-10-31Dr. Matthew Gerrard Winston FrohnNon-Executive Director
2022-03-03Mr. Martin Henry Diggle Non-Executive Director
2021-10-29Dr. Sally Elizabeth AdamsExecutive Director,Development Director
2021-07-28Dr. Clifford Michael HollowayExecutive Director,Chief Executive Officer

Scancell Holdings PLC Contact Details

Company NameScancell Holdings PLC
AddressRobert Robinson Avenue, John Eccles House, Oxford Science Park, Oxford, OX4 4GP
Telephone+44 1865338069

Scancell Holdings PLC Advisors

Nominated AdviserPanmure Gordon (UK) Ltd
Phone+44 2078862500
StockbrokerPanmure Gordon (UK) Ltd
Phone+44 2078862500
Financial PR AdviserFTI Consulting Inc
Phone+44 2037271000
Fax+44 2037271007
Phone(020) 7842 8000
Fax(020) 7842 8080
RegistrarS.L.C Registrars Ltd
Phone+44 1903706150
Financial PR AdviserVisible Value LLP
AuditorChampion Accountants LLP
Phone(01244) 404 420
Fax(01244) 404 440